Australia has become the first country in the world to fund a psychedelic-assisted treatment for PTSD through a government health scheme. The Department of Veterans’ Affairs (DVA) now covers MDMA-assisted psychotherapy for veterans with PTSD, and psilocybin-assisted psychotherapy for treatment-resistant depression, when standard treatments haven’t worked. It’s a significant shift, and one worth understanding regardless of whether it applies to you directly.
Why this matters
PTSD doesn’t respond the same way for everyone. Studies suggest that a substantial share of people with PTSD don’t fully respond to the first-line treatments currently available — trauma-focused talk therapies and standard medications — and for some, multiple rounds of treatment bring little relief. Veterans and first responders are disproportionately affected, with PTSD prevalence in that population running well above the general community rate.
That gap between how many people need effective treatment and how many actually get better with existing options is exactly what’s driving interest in new approaches, including psychedelic-assisted therapy.
Photo by Pierre Bamin on Unsplash
What’s changed
MDMA and psilocybin were rescheduled for therapeutic use in Australia in 2023, allowing specially authorised psychiatrists to prescribe them under strict conditions. Off the back of that, the DVA has now approved direct government funding for eligible veterans, delivered as part of a broader veterans’ mental health and rehabilitation package.
Importantly, this isn’t a first-line treatment or something people can simply request. It’s reserved for veterans who have already tried standard treatments without success, and it must be delivered by authorised providers as part of structured, intensive psychotherapy — not the medication alone. Early data collected through Australia’s Authorised Prescriber Scheme reportedly shows no serious adverse events recorded among patients treated so far, and researchers at the Australian National University are building a real-world evidence dataset to track outcomes as more veterans go through the program.
What the evidence says more broadly
Psychedelic-assisted therapy for PTSD is still an emerging field. Clinical trial results for MDMA-assisted therapy have been promising in some studies, but the evidence base is younger and smaller than for established treatments, and regulators overseas have been more cautious — the U.S. FDA, for example, rejected an application to approve MDMA for PTSD in 2024, citing a need for more research. That divergence is part of why Australia’s approach is being closely watched internationally, with some researchers and advocates suggesting other countries may face growing pressure to follow if Australian outcome data holds up.
A practical message for readers
If you have PTSD and standard treatment hasn’t worked for you, this is a development worth knowing about, but it’s not a shortcut or a quick fix — it’s an intensive, closely supervised treatment for people who meet specific criteria, and access outside the veteran and authorised-clinic pathway remains limited. If you’re curious whether it could be relevant to your situation, that’s a conversation to have with your treating psychiatrist or GP, not something to pursue informally.
Whatever stage you’re at with PTSD treatment — just starting, mid-way through something that isn’t working, or exploring newer options — the field is moving, and today’s “nothing left to try” isn’t necessarily true a year or two from now.
Has anyone here explored newer PTSD treatment options, or is standard therapy what’s worked for you?